Project Grant R43AI188915
Award Date 8/7/25
Completion Date 7/31/26
Dollars Obligated $305K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $651,384 to develop a programmable technology platform that will transform antibody-based therapeutics. The goal is to establish a foundation for next-generation protein countermeasures and therapeutics by synergistically merging two synthetic biology...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will provide $386,194 from July 1, 2025 to June 30, 2027 to the Massachusetts Institute of Technology (MIT) to develop synthetic methods for constructing bispecific "antibody-bottlebrush conjugates" (BSABCs). The goal is to investigate the effects of inter-antigen distance and targeting specificity on...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scribe Biosciences, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput antibody discovery platform against cell membrane-bound proteins. Scribe Biosciences, a for-profit company specializing in microfluidics and biomedical engineering, will utilize its proprietary Microenvironment on Demand (MOD) technology to assemble over 100,000 single-cell...
- This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
- This $481,250 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant will fund the development of new antimicrobial small molecule compounds that recruit the immune system to target bacteria. Key activities include the biochemical, biophysical, and cell biology characterization of these chimeric molecules formed by joining bacterial binding agents with...
- This Project Grant award of $156,080 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The award supports research to uncover the underlying biology and key properties that define "broadly neutralizing" antibodies - those that can recognize and neutralize a wide range of related pathogens. Using SARS-CoV-2 as a model, the research aims to determine whether the...
- The National Institute of Allergy and Infectious Diseases (NIAID), as part of the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $300,000 Project Grant to Cellergy Pharma Inc. The grant, effective February 1, 2025 through January 31, 2027, supports the development of a bispecific antibody drug targeting IgE-producing B cells to treat severe allergic diseases. The key products and services to be delivered under this Phase I grant include: Determining the...
- This $342,776 federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop advanced data science methods and an automated pipeline for efficient and high-performance monoclonal antibody (mAb) formulation. The goals are to create a self-driving bioformulation laboratory that leverages artificial intelligence, machine...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...